**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 50124**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

***Clostridium butyricum* alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells**

Zhao Q *et al*. LPDCs-associated IBS probiotic treatment

Qin Zhao, Wen-rong Yang, Xiao-hong Wang, Gai-qin Li, Lei-qi Xu, Xiao Cui, Yang Liu, Xiu-li Zuo

**Qin Zhao, Lei-qi Xu, Xiao Cui, Xiu-li Zuo,** Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, Shandong Province, China

**Qin Zhao, Xiao-hong Wang, Gai-qin Li,** Department of Gastroenterology, Taian City Central Hospital, Taian 271000, Shandong Province, China

**Wen-rong Yang,** Department of Clinical Nutrition, Taian City Central Hospital, Taian 271000, Shandong Province , China

**Yang Liu,** Department of Medicine, Beijing 316 Hospital, Beijing 100093, China

**ORCID:** Qin Zhao (0000-0001-8542-2285); Wen-rong Yang (0000-0002-6495-5418); Xiao-hong Wang (0000-0002-6348-938X); Gai-qin Li (0000-0003-2924-2815); Lei-qi Xu (0000-0001-6286-6545); Xiao Cui (0000-0002-1416-8758); Yang Liu (0000-0002-4561-7421); Xiu-li Zuo (0000-0002-6633-800X).

**Author contributions:** Zhao Q, Zuo Xl and Xu Lq formulated the study concept, designed the study, and guaranteed the integrity of the entire study; Zhao Q and Cui X contributed to experimental studies and data acquisition; Zhao Q, Cui X, and Xu Lq contributed to literature research and manuscript editing; Zhao Q contributed to definition of intellectual content and clinical studies and manuscript preparation; Zhao Q, Cui X, Wang Xh, and Yang Wr contributed to data analysis; Zhao Q, Cui X, Wang Xh, Li Gq, and Liu Y contributed to statistical analysis; Zuo Xl and Xu Lq contributed to manuscript review; all authors approved the final version of the manuscript.

**supported by** the National Natural Science Foundation of China, No. 81770538 and No. 81570485; and Key Research and Development Program of Shandong Province, No. 2017CXGC1215.

**Institutional animal care and use committee statement:** This study was approved by the Institutional Animal Ethical Review Board of Taian City Central Hospital.

**Conflict-of-interest statement:** The authors declare no conflicts of interest related to this manuscript or its publication.

**ARRIVE guidelines statement:** The ARRIVE Guidelines have been adopted.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Xiu-li Zuo, MD, PhD, Associate Professor, Chief Doctor,** Department of Gastroenterology, Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan 250012, Shandong Province, China. zuoxiuli\_s@163.com

**Telephone:** +86-531-88369277

**Fax:** +86-531-88369277

**Received:** July 10, 2019

**Peer-review started:** July 10, 2019

**First decision:** August 5, 2019

**Revised:** August 17, 2019

**Accepted:** August 24, 2019

**Article in press:** August 24, 2019

**Published online:** September 28,2019

**Abstract**

***Background***

Irritable bowel syndrome (IBS) is one of the most common functional gastroenterological diseases characterized by abnormal visceral sensitivity and low-grade inflammation. The role of *Clostridium butyricum* (*C. butyricum*) in reducing intestinal low-grade inflammation *via* immune pathways has been well defined. However, the detailed mechanisms of the effects of *C. butyricum* on intestinal mucosal immunity, especially on immune cells of the lamina propria, remain unclear. Dendritic cells (DCs), which are important immune cells, secrete proinflammatory cytokines (IL-1β, IL-6, and others) and express T cell immunoglobulin and mucin domain-3 (TIM3), promoting proliferation and activation of DCs, and mediating Th1 and Th17 inflammatory responses.

***Aim***

To investigate the role of DCs in the development of IBS in a rat model and to understand the regulation of DCs after *C. butyricum* intervention.

***Methods***

An IBS animal model was established using C57BL/6 mice, and *C. butyricum* was continuously administered *via* the intragastric route to simulate different intestinal immune states. Intestinal visceral hypersensitivity and histopathology were assessed using the abdominal withdrawal reflex (AWR) test and hematoxylin & eosin (H&E) staining, respectively. The expression of proinflammatory cytokines (IL-1β and IL-6) and TIM3 was analyzed by Western blot analysis and real-time PCR. Flow cytometry was applied to analyze the quantity, function, and membrane molecule TIM3 of the lamina propria dendritic cells (LPDCs). The regulatory effect of *C. butyricum* was verified in bone marrow-derived dendritic cells by *in vitro* experiments.

***Results***

The secretion of proinflammatory cytokines (IL-1β and IL-6) in mice with IBS was significantly increased compared with that of the control group, which suggested that the intestinal mucosa in mice with IBS was in a low-grade inflammatory state. The expression of CD11C+CD80+ and CD11c+TIM3+ in intestinal LPDCs in mice with IBS increased significantly. Meanwhile, the cytokines (IL-1β and IL-6) were significantly reduced after the intervention with probiotic *C. butyricum.* The amount and function of LPDCs and the TIM3 on the surface of the LPDCs were decreased with the alleviation of the intestinal inflammatory response.

***Conclusion***

The results suggest that *C. butyricum* regulates the amount and functional status of LPDCs in the intestinal mucosa of mice with IBS, and therefore modulates the local immune response in the intestine.

**Key words:** *Clostridium butyricum*; Irritable bowel syndrome; lamina propria dendritic cells; T cell immunoglobulin and mucin domain-3; proinflammatory cytokines

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this study, we revealed that *Clostridium butyricum* can regulate the number and functional status of lamina propria dendritic cells in the intestinal mucosa of mice with irritable bowel syndrome, and therefore modulate the local immune response in the intestine.

Zhao Q, Yang Wr, Wang Xh, Li Gq, Xu Lq, Cui X, Liu Y, Zuo Xl. *Clostridium butyricum* alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells. *World J Gastroenterol* 2019; 25(36): 5469-5482

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i36/5469.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i36. 5469

**Introduction**

Irritable bowel syndrome (IBS) is one of the most common functional gastroenterological diseases which affects approximately 15% of the population worldwide[[1](#_ENREF_1)]. IBS is thought to result from the activation of the mucosal immune system and the disruption of the epithelial barrier by the intestinal microbiota[[2-4](#_ENREF_2)]. Previous studies have reported that the intestinal flora interacts with the intestinal immune system to maintain intestinal homeostasis[[5](#_ENREF_5),[6](#_ENREF_6)]. Therefore, an intervention with probiotics may be salutary for IBS treatment.

The probiotic *Clostridium butyricum* (*C. butyricum*)is a type of Gram-positive anaerobic bacterium, which has been used for the treatment of IBS in clinical settings. It has been documented that the intragastric administration of *C. butyricum* significantly reduces intestinal inflammation and ameliorates the intestinal microbiota[[7-9](#_ENREF_7)]. Besides, *Clostridium* species have been reported to affect the accumulation of intraepithelial lymphocytes (IELs) in the colon[[10](#_ENREF_10)] and to increase the number of Treg cells, thereby inhibiting the expression of inflammatory cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-12, IFN-r, IL-1β, and IL-6) and up-regulating the expression of inhibitory cytokines (IL-10)[[11-15](#_ENREF_11)]. Other studies provided evidence that *Clostridium* speciesmight suppress the intestinal inflammatory response *via* immune pathways[[15-17](#_ENREF_15)].

The lamina propria dendritic cells (LPDCs) are important antigen-presenting cells in the intestines. They are now recognized to be essential for innate and acquired immunity[[18](#_ENREF_18),[19](#_ENREF_19)]. LPDCs have a particular capacity to sample antigens from peripheral tissues and efficiently activate resting T cells and direct T cell bias (Th1, Th2, and Th17)[[20](#_ENREF_20)]. In the steady state, LPDCs induce the differentiation of regulatory T cells to produce IL-10 and transform growth factor-beta (TGF-beta)[[19](#_ENREF_19),[21](#_ENREF_21)]. Studies on LPDCs in IBS or IBD patients have revealed that LPDCs were significantly increased and the co-stimulatory molecules (CD80, CD86, and MHCII) were upregulated, the secretions of IFN-g, IL-1β, IL-6, IL-12, and TNF-α were increased, and the migration and proliferation of CD4+ T cells were enhanced. These regulations were found to be correlated with Th1 and Th17 inflammatory responses[[22-24](#_ENREF_22)]. The immunoregulatory function of LPDCs is related to their subpopulation and the surface receptors[[25](#_ENREF_25)]. The local microenvironment likely plays an important role in defining the phenotype and activation of dendritic cells (DCs).

Recently, detailed analyses of the effect of *C. butyricum* on LPDCs have been mainly focused on cytokines; *e.g.*, *C. butyricum* was revealed topromot Treg cell generation in the intestine through the induction of TGF-β1 from LPDCs[[16](#_ENREF_16)] . This strain negatively regulated the expression of IL-12/IL-23p40[[26](#_ENREF_26)]. However, to date, there is no study that reveals the effect of *C. butyricum* on surface molecules of LPDCs . T cell immunoglobulin and mucin domain-3 (TIM3) is an immunoregulatory factor expressed on the surface of DCs[[27](#_ENREF_27),[28](#_ENREF_28)]. It upregulates the secretion of the proinflammatory cytokines (TNF-α and IL-1β), promotes cell proliferation and activation, and eliminates various pathogens[[29-32](#_ENREF_29)]. To our best known, the regulatory effect of *C. butyricum* on TIM3 has not been reported until now.

This study aimed to investigate the role of the probiotic *C. butyricum* in regulating the quantity and function of LPDCs and the membrane molecule TIM3 of the LPDCs in mice with IBS and to further elucidate the effects of the probiotic *C. butyricum* on the local immune response in the intestinal mucosa.

**Materials and methods**

***Induction of PI-IBS in mice***

Twenty-four C57BL/6 male mice (aged 6-8 wk) were randomly divided into four groups (normal control, IBS, IBS + *C. butyricum* intervention, and IBS + normal saline (NS) intervention (*n* = 6 per group)). Pentobarbitone (50 mg/kg intraperitoneal administration) was used to establish deep anesthesia in these mice[[33](#_ENREF_33)]. A plastic catheter (outer diameter = 4 mm) was inserted into the descending colon of each mouse to a depth of 4-6 cm from the anus. 2,4,6-trinitrobenzenesulfonic acid (TNBS) (P2297, Sigma, Shanghai; 0.1 mL of 5% (w/v), diluted to 0.2 mL using 50% ethanol) was slowly instilled. In the control group, the clysis was replaced by an injection of NS. For the other groups, the mice were inverted for 10 min to prevent drug leakage after clysis. Four weeks after TNBS administration, *C. butyricum* (QingDao EastSea Pharmaceutical Co., Ltd., QinDao, China) was continuously administered *via* the intragastric route to 6 mice during 1 wk (200 μl/d; concentration of live bacteria concentration, 1 × 108 CFU/ml). NS in the same amount was administered to the mice in the control group. Hematoxylin & eosin (H&E) staining and the abdominal withdrawal reflex (AWR) test were used to evaluate the degree of colon inflammation.

***H&E staining***

To evaluate the inflammatory grade of colon tissue in the four groups, formalin-fixed mouse colon tissue was embedded in paraffin, sectioned at 4 μm, and stained with H&E (Beijing Coribo Technology Co. Ltd., Beijing, China) for histological analysis to assess conditions such as epithelial erosion, crypt loss, and inflammatory infiltration with lymphocytes. A pathologist blindly assessed and assigned an inflammatory grade to each section.

***AWR test***

The AWR test was perfomed at day 28 to assess visceral hyperalgesia in response to colorectal distention (CRD)[[34](#_ENREF_34)]. A disposable silicon balloon-urethral catheter for pediatric use (6 Fr, Terumo, Tokyo, Japan) was used. Mice were briefly anesthetized with ether. The balloon was inserted into the rectum until the catheter was positioned to the anus (2 cm distal from the end of the balloon). The catheter was fixed to the base of the tail to prevent detachment. After waking up and adapting for 1 hours, CRD was performed in a stepwise fashion. An ascending-limit phasic distention (0.25, 0.35, or 0.50 ml) was applied in 30 s every 4 min. The AWR was semiquantitatively scored as previously described[[35](#_ENREF_35)]. The AWR score was assigned as follows: 0 = no behavioral response to distension; 1 = brief head movements followed by immobility; 2 = contraction of abdominal muscles without lifting of the abdomen; 3 = lifting of the abdomen; 4 = body arching and lifting of the pelvic structure.

***Extraction of LPDCs***

The mice were sacrificed by cervical dislocation, and their colon, rectum, fat, and mesentery were extracted. The colon was washed and cut into 5-mm sections, incubated in a solution containing 2% fetal calf serum (FCS) and 5 mmol/L EDTA (Sigma) for 30 min**.** The tissue fragments were filtered through a screen to remove the epithelial cells and were collected into a small bottle where they were washed, cut up, and incubated in RPMI-1640 containing 2% FCS, collagenase IV (4 mg/mL, Solarbio, Beijing, China), and DNase I (10 μg/mL, Solarbio) for 30 min. The suspension was stirred at 37°C, then the released cells were collected through a 300-mesh screen. The isolated cells were separated on a discontinuous 40%/75% Percoll (Sigma) gradient. The typical yield was 2-3 × 106 lymphocytes/mouse.

***Culture of bone marrow-derived DCs (BMDCs)***

DCs were generated *in vitro* from bone marrow cells from 6- to 8-wk-old wild-type C57BL/6 mice[[36](#_ENREF_36)] and were resuspended in 10% FCS medium (RPMI-1640: Gibco, Los Angeles, United States; GM-CSF: Biosciences, San Jose, CA, United States, [20 ng/ml]; IL-4: PeproTech, Rocky Hill, United States, [10 ng/ml]; penicillin [100 U/ml], and streptomycin [100 U/ml]). The cells were cultivated in a 6-well plate in an environment containing 5% CO2 at 37 ℃. A half volume of culture medium was replaced every other day. On the 7th day, penicillin-streptomycin was removed while replacing the medium. The collected DCs were separately co-cultured with 100 μl of the *C. butyricum* culture supernatant and 100 µl (concentration, 1 × 108 CFU/ml) of the live bacterial suspension for 4 hours and then stimulated with 0.1 µg/mL of lipopolysaccharide (LPS; Sigma–Aldrich) for 3 hours. The DC cells were subsequently collected, and the supernatant was cultured for evaluation using flow cytometry and enzyme-linked immunosorbent assay (ELISA).

***Flow cytometry***

The colonic lamina propria cells were collected and suspended (1 × 106 cells/ml) in PBS with 2% FCS. The DCs were marked with anti-CD11c- FITC, anti-CD80-PEcy5.5, and anti-TIM3-APC (eBioscience, CA, United States). The stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, USA), and the data were collected and analyzed with FlowJo software (Tree Star Inc., Stanford, United States).

***Western blot analysis***

The colon tissues were homogenized and ultrasonically treated on ice for cell lysis and protein extraction. After determining the protein content, the degeneration process was performed at 100 ℃ for 5 min. The proteins were separated using 10% SDS-PAGE and transferred to PVDF membranes (0.4-5 μm pore size; Millipore, United States). After blocking with 5% skimmed milk, the membranes were incubated with rabbit anti-TIM3 (1:2000), anti-IL-1β (1:2000), and anti-IL-6 (1:2000) antibodies (Abcam, Cambridge, UK)at 4 °C overnight and then incubated with secondary antibodies labeled with horseradish peroxidase (1:10000, Zhongshan Gold Bridge, Beijing, China) for 2 h at room temperature. The immunoblots were detected using an enhanced chemiluminescent substrate (Millipore) on the ChemiDoc MP system (Bio-Rad, United States). All of the detected protein bands were standardized against β-actin. The semiquantification of each band was performed using ImageJ NIH software (National Institutes of Health, Bethesda, MD, United States).

***ELISA***

Different groups of DC culture supernatants were collected and centrifuged at 300 *g* for 10 min at 4 °C. The supernatants were collected and stored at -80°C until use. According to the manufacturer’s instructions, an ELISA kit (Tianjin Anoric Biotechnology CO, ltd.) was used to measure the mucosal cytokine levels of IL-1β and IL-6. The results are expressed as total protein (pg/ml).

***Quantitative real-time PCR***

Total RNA was extracted using Trizol (Invitrogen, San Diego, CA, USA). The total RNA (1 μg) was reverse transcribed into cDNA using the ReverTra Ace® qPCR RT Kit (TOYOBO, Japan) in a Mastercycler thermal cycler (Eppendorf, German). Real-time PCR was performed using the SYBR Green reagent (Takara, Japan) in a fluorescence thermocycler (LightCycler; Roche Diagnostics, Mannheim, Germany). The relative mRNA expression was determined after normalizing to β-actin levels using the 2-ΔΔCT method with the following sequence-specific primers: TIM3 forward, 5′-GC TAC GTC AAC AGC CAG CAG-3′ and reverse, 5′-CCA ATG AGG TTG CCA AGT GA-3′; IL-1β forward, 5′-GAA CCT AGC TGT CAA CGT GTG G-3′ and reverse, 5′-GCA ATG TGC TGG TGC TTC AT-3′; IL-6 forward, 5′-GCT AAG GAC CAA GAC CAT CCA-3′ and reverse, 5′-GAC CAC AGT GAG GAA TGT CCA-3′

***Statistical analysis***

The statistical analyses were performed using SPSS Statistics 17.0 software. All the values are expressed as the mean ± standard error of the mean (SEM). For multiple comparisons, one-way analysis of variance (ANOVA) was applied. The comparisons with *P* < 0.05 were considered statistically significant.

**Results**

***Histopathological findings of the colonic mucosa***

As shown in Figure 1, histological examination showed no difference with regard to morphology (epithelium erosion, crypt loss, and inflammatory infiltration with lymphocytes) between the normal control and IBS groups in H&E staining. Furthermore, no difference in morphology was observed between the IBS + *C. butyricum* and IBS + NS groups.

***C. butyricum alleviates intestinal visceral hypersensitivity in TNBS-induced IBS mice***

To determine whether *C. butyricum* treatment could reduce intestinal visceral hypersensitivity in IBS, *C. butyricum* was continuously administered *via* the intragastric route to IBS groups during 1 week. The degree of colon pain threshold pressures was assessed by the AWR test. As shown in Figure 2, the AWR scores for the IBS group were significantly increased compared with those for the normal control group at distention volumes of 0.25, 0.35, and 0.5 ml (*P* < 0.05). Similarly, *C. butyricum* treatment significantly decreased the AWR scores at the same distention volumes (*P* < 0.05).

***C. butyricum suppresses the production of proinflammatory cytokines in TNBS-induced IBS mice***

We further investigated the effects of *C. butyricum* on the expression of IL-1β and IL-6 proteins and their corresponding mRNAs in mice with TNBS-induced IBS. As shown in Figure 3, inflammatory cytokines (IL-1β and IL-6) were found to be significantly higher in the colon of mice with IBS compared with those in the normal control group (*n* = 6, *P* < 0.01). However, treatment with *C. butyricum* significantly reduced the expression of IL-1β and IL-6 proteins and the corresponding mRNAs (*n* = 6, *P* < 0.05). These results suggested that the intestinal mucosa in mice with IBS was in a low-grade inflammatory state. And *C. butyricum* might suppress the production of proinflammatory cytokines induced by TNBS stimulation.

In the absence of colonic mucosa histopathology, low-grade inflammation together with visceral hypersensitivity and increased inflammatory cytokines were observed in the PI-IBS animal model.

***C. butyricum regulates the quantity and function of LPDCs in mice with TNBS-induced IBS***

To evaluate the effects of *C. butyricum* on colonic LPDCs, LPDCs were extracted and analyzed using flow cytometry. Figure 4A-B shows that TNBS induced an increase in the number of CD11c+ LPDCs (IBS group: 56.90% ± 1.86% and IBS + NS group: 52.70% ± 1.13%) compared with that of the normal control group (36.43% ± 1.67%) (*n* = 6, *P* < 0.001). After treatment with *C. butyricum*, the number of CD11c+ LPDCs markedly decreased (34.15±1.54%), which was similar to that of the normal control group (*n* = 6, *P* > 0.5). Simultaneously, the amount of CD11c+CD80+ LPDCs increased in the IBS group (48.23% ± 2.92%) and in the IBS + NS group (47.20% ± 3.10%) compared with that of the normal control group (29.32% ± 1.19%). However, the amount of CD11c+CD80+ LPDCs was restricted by the *C. butyricum* treatment (28.37% ± 1.39%) (*n* = 6, *P* < 0.001).

Also, we investigated the level of an immunoregulatory molecule, TIM3, in LPDCs. Flow cytometry analysis was used to quantify the number of CD11c+TIM3+ LPDCs. Figure 4C shows that the levels of CD11c+TIM3+ LPDCs at the IBS low-grade inflammatory stage were significantly increased compared with that of the normal control group (normal control group: 25.60% ± 1.42%; IBS group: 38.52% ± 2.23%) (*n* = 6, *P* < 0.01). *C. butyricum* reduced the increase in the number of CD11c+TIM3+ LPDCs of the IBS group (IBS + *C. butyricum* group: 26.52% ± 1.78% and IBS + NS group: 37.40 ± 1.53%) (*n* = 6, *P* < 0.01) to match the number of TIM3+CD11c+ LPDCs of the normal control group (*n* = 6, *P* > 0.05). The other two methods (real-time PCR and Western blot analysis) also confirmed this conclusion at the protein and RNA levels (Figure 4E and F).

Collectively, based on our results, we concluded that *C. butyricum* not only reduced the number and function of LPDCs in TNBS-induced IBS mice but also down-regulated the expression of the immunoregulatory molecule TIM3 in LPDCs.

***C. butyricum alleviates the proinflammatory activation of BMDCs in vitro***

We examined the effect of *C. butyricum* on the BMDCs using flow cytometry analysis. Figure 5A-D shows that the *C. butyricum* treatment significantly decreased the number of CD11c+TIM3 + BMDCs (19.28% ± 1.57%) compared to that of the LPS group (43.33% ± 4.59%) (*n* = 6, *P* < 0.01). The number of CD11c+CD80+ DCs was also decreased in the BMDCs + *C. butyricum* group (*n* = 6, *P* < 0.001). The production of proinflammatory cytokines (IL-1β and IL-6) was also examined in BMDCs using ELISA. Figures 5E and F shows that *C. butyricum* markedly inhibited the LPS-induced secretion of IL-1β and IL-6 (*n* = 6, *P* < 0.05).

These results indicated that *C. butyricum* inhibited the proliferation and activation of BMDCs and reduced the secretion of pro-inflammatory cytokines, but down-regulated the expression of the TIM3 on the membrane of BMDCs.

**Discussion**

IBS is related to various physiological alterations such as changes in the composition of gut microbiota, immune activation, gastrointestinal (GI) dysmotility, hypersensitivity, and the gut mucosal barrier[[2](#_ENREF_2),[4](#_ENREF_4),[37](#_ENREF_37),[38](#_ENREF_38)]. Although extensive studies have recently focused on the correalations between intestinal microenvironment and immune activation, associated mechanisms have been rarely reported.

Probiotic *C. butyricum* produces butyric acid, which plays an important role in intestinal function by enhancing the intestinal barrier, improving the intestinal microbiota, regulating the immune system, and promoting gastrointestinal motility[[39](#_ENREF_39),[40](#_ENREF_40)]. In this study, we found that in TNBS clysis-induced PI-IBS mice, the intragastric administration of *C. butyricum* significantly alleviated intestinal visceral hypersensitivity and reduced low-grade mucosal inflammation. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor[[41](#_ENREF_41)]. Particularly, the changes in the cytokines IL-1β and IL-6 secreted by LPDCs contribute to the development of IBS[[42](#_ENREF_42),[43](#_ENREF_43)]. Our results showed that the important proinflammatory cytokines IL-1β and IL-6 were significantly increased in a murine model of IBS (*n* = 6, *P* < 0.01). However, these two inflammatory cytokines were both significantly suppressed (*n* = 6, *P* < 0.01) after the intervention with *C. butyricum*. Such results provide evidence for the anti-inflammatory activity of *C. butyricum*[[7-9](#_ENREF_7)].

LPDCs are known to play a pivotal role in the regulation of the mucosal immune response[[22](#_ENREF_22)]. Animal studies have highlighted the role of DCs in IBS pathogenesis based on the findings of induced visceral hypersensitivity and T cell activation[[23](#_ENREF_23),[24](#_ENREF_24)]. It has been shown previously that the quantity of DCs in patients with IBS and IBD increased significantly, and the mature co-stimulatory molecules (CD80, CD86, and MHCII) were upregulated. Meanwhile, the secretion of the inflammatory cytokines was increased, and the migration and proliferation of CD4+ T cells were enhanced, resulting in the mediation of the Th1 and Th17 inflammatory responses[[44-46](#_ENREF_44)]. In this study, we found that the expression of CD11c+ LPDCs and CD11c+CD80+ LPDCs in the colon of IBS mice was significantly higher than that of the normal control mice (*n* = 6, *P* < 0.001). These results suggested enhanced proliferation and activation of LPDCs in the local intestinal mucosa of IBS animals. Our results also demonstrated that LPDCs participated in and promoted the intestinal inflammatory immune response in PI-IBS. These findings are consistent with the results of previous studies[[47](#_ENREF_47)].

In addition, we also found that after receiving *C. butyricum* intervention, the quantity of LPDCs was significantly decreased, and the co-stimulatory molecule CD80 was downregulated (*n* = 6, *P* < 0.001) in mice. These results indicate that *C. butyricum* alleviates the intestinal low-grade inflammation by regulating the functional status of LPDCs in mice with TNBS-induced IBS. Further investigation of the local microenvironment will be needed for the confirmation of DC phenotype and activation.

The immunoregulatory function of LPDCs is related to their subpopulation and surface receptors. TIM3 is an immune-regulatory factor. Recent studies have revealed that TIM3 expressed on macrophages and DCs upregulates the secretion of proinflammatory cytokines (TNF-α, IL-1β, IL-6 and so on) and promotes cell proliferation, activation, and phagocytosis, which result in enhanced elimination of different pathogens[[29](#_ENREF_29),[31](#_ENREF_31),[32](#_ENREF_32),[43](#_ENREF_43)]. Anti-TIM3 mAb reduces the secretion of IL-12p70 in LPS-induced BMDCs and inhibits the upregulation of CD40, CD80, and CD86 expression in BMDCs[[48](#_ENREF_48)]. The expression of TIM3 is upregulated after being stimulated to mature *via* the *in vitro* administration of IL-15 or IL-12 and IL-18 for immature natural killer cells[[27](#_ENREF_27),[28](#_ENREF_28),[49](#_ENREF_49)]. Proinflammatory TIM3 is highly expressed in several inflammatory diseases[[50](#_ENREF_50),[51](#_ENREF_51)]. TIM3/Gal9 induces the generation of the cytokines IL-1β, IL-6, and TNF-α through caspase-1, and the induced IL-1β further promotes the generation and activation of other cytokines by autocrine feedback[[30](#_ENREF_30),[52](#_ENREF_52)]. To our best known, this is the first study that reports the role of TIM3 in LPDCs in the pathogenesis of IBS and the regulatory effect of *C. butyricum* on TIM3. In this study, the results demonstrate that the expression levels of TIM3 on LPDCs are positively correlated with intestinal low-grade inflammation according to the comparision among four different intestinal immune states. The levels of CD11c+TIM3+ LPDCs are significantly increased in the colon of mice with IBS. However, the CD11c+TIM3+ LPDCs are significantly reduced after the alleviation of the intestinal low-grade inflammation by *C. butyricum* intervention (*n* = 6, *P* < 0.01), but no significant difference is observed when compared to the normal control group (*n* = 6, *P* > 0.05).

Combined with previous studies, the regulatory effect of *C. butyricum* on DCs has been verified in the following cell tests. Compared with the BMDC + LPS group, through the stimulation of *C. butyricum-*treated BMDCs with LPS, the expression of CD11c+, CD11c+CD80+, and CD11c+TIM3+ LPDCs was also significantly downregulated. These results suggest that *C. butyricum* not only reduces the number of BMDCs and inhibits their functional status but also significantly reduces the expression of TIM3. Thus, we have reason to believe that DCs play an important regulatory role in the immune response and are regulated by the microenvironment.

In conclusion, our results indicate that intestinal LPDCs play an important role in the pathogenesis of IBS, and *C. butyricum* can alleviate intestinal inflammatory immune responses by regulating the amount and function of LPDCs and the expression of TIM3 on the surface of LPDCs. Our research not only provides an in-depth understanding of the local immune response mechanism in the intestinal mucosa of IBS patients, but also provides a newperspective for the application of probiotic *C. butyricum* in the treatment of IBS.

**ARTICLE HIGHLIGHTS**

***Research background***

Irritable bowel syndrome (IBS) affects 7% to 21% of the general population. It is a chronic diseases characterized by abnormal visceral sensitivity and low-grade inflammation. The role of *Clostridium butyricum* (*C. butyricum*) in reducing intestinal low-grade inflammation *via* immune pathways has been well defined. However, the mechanism has not been clearly elucidated.

***Research motivation***

To test the hypothesis that the function of dendritic cells (DCs) changes in the development of IBS and to understand the regulation of DCs after *C. butyricum* intervention.

***Research objectives***

We aimed to investigate the mechanism of DCs in the development of IBS in a mice model and to understand the regulation of DCs after *C. butyricum* intervention.

***Research methods***

An IBS animal model was established using C57BL/6 mice, and *C. butyricum* was continuously administered *via* the intragastric route to simulate different intestinal immune states. Intestinal visceral hypersensitivity and histopathology were assessed using the abdominal withdrawal reflex test and hematoxylin & eosin staining, respectively. The expression of proinflammatory cytokines (IL-1β and IL-6) and TIM3 was analyzed by Western blot analysis and real-time PCR. The flow cytometry was applied to analyze the quantity, function, and membrane molecule TIM3 of the LPDCs. The regulatory effect of *C. butyricum* was verified in BMDCs by *in vitro* experiments.

***Research results***

We found that the IBS mouse model has abundant expression of IL-1β, IL-6, and CD11C+CD80+ and CD11c+TIM3+ LPDCs compared with the control group. Further investigation showed that probiotic *C. butyricum* reduced the expression of cytokines (IL-1β and IL-6). The amount and function of LPDCs and the membrane molecule TIM3 of the LPDCs were decreased with the alleviation of the intestinal inflammatory response.

***Research conclusion***

This study demonstrated that *C. butyricum* could induce the expression of various proinflammatory cytokines *via* regulating the amount and the functional status of LPDCs in the intestinal mucosa of mice with IBS.

***Research perspectives***

This research not only provides an in-depth understanding of the local immune response mechanism in intestinal mucosa of IBS humans, but also provides a new perspective for the application of probiotic *C. butyricum* in the treatment of IBS.

**References**

1 **Sperber AD**, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Hungin APS, Kang JY, Minhu C, Schmulson M, Bolotin A, Friger M, Freud T, Whitehead W. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. *Gut* 2017; **66**: 1075-1082 [PMID: 26818616 DOI: 10.1136/gutjnl-2015-311240]

2 **Ng QX**, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). *J Inflamm Res* 2018; **11**: 345-349 [PMID: 30288077 DOI: 10.2147/JIR.S174982]

3 **Jeffery IB**, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut* 2012; **61**: 997-1006 [PMID: 22180058 DOI: 10.1136/gutjnl-2011-301501]

4 **Vivinus-Nébot M**, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hébuterne X, Piche T. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. *Gut* 2014; **63**: 744-752 [PMID: 23878165 DOI: 10.1136/gutjnl-2012-304066]

5 **Round JL**, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009; **9**: 313-323 [PMID: 19343057 DOI: 10.1038/nri2515]

6 **Goto Y**, Ivanov II. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk. *Immunol Cell Biol* 2013; **91**: 204-214 [PMID: 23318659 DOI: 10.1038/icb.2012.80]

7 **Sisson G**, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. *Aliment Pharmacol Ther* 2014; **40**: 51-62 [PMID: 24815298 DOI: 10.1111/apt.12787]

8 **Hudson LE**, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. *Clin Microbiol Rev* 2017; **30**: 191-231 [PMID: 27856521 DOI: 10.1128/CMR.00049-16]

9 **Sun YY**, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *Sci Rep* 2018; **8**: 2964 [PMID: 29445178 DOI: 10.1038/s41598-018-21241-z]

10 **Umesaki Y**, Setoyama H, Matsumoto S, Imaoka A, Itoh K. Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. *Infect Immun* 1999; **67**: 3504-3511 [PMID: 10377132]

11 **Atarashi K**, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 2013; **500**: 232-236 [PMID: 23842501 DOI: 10.1038/nature12331]

12 **Atarashi K**, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 2011; **331**: 337-341 [PMID: 21205640 DOI: 10.1126/science.1198469]

13 **Round JL**, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science* 2011; **332**: 974-977 [PMID: 21512004 DOI: 10.1126/science.1206095]

14 **Arpaia N**, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013; **504**: 451-455 [PMID: 24226773 DOI: 10.1038/nature12726]

15 **Hayashi A**, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, Hibi T, Roers A, Yagita H, Ohteki T, Yoshimura A, Kanai T. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. *Cell Host Microbe* 2013; **13**: 711-722 [PMID: 23768495 DOI: 10.1016/j.chom.2013.05.013]

16 **Kashiwagi I**, Morita R, Schichita T, Komai K, Saeki K, Matsumoto M, Takeda K, Nomura M, Hayashi A, Kanai T, Yoshimura A. Smad2 and Smad3 Inversely Regulate TGF-β Autoinduction in Clostridium butyricum-Activated Dendritic Cells. *Immunity* 2015; **43**: 65-79 [PMID: 26141582 DOI: 10.1016/j.immuni.2015.06.010]

17 **Hua MC**, Lin TY, Lai MW, Kong MS, Chang HJ, Chen CC. Probiotic Bio-Three induces Th1 and anti-inflammatory effects in PBMC and dendritic cells. *World J Gastroenterol* 2010; **16**: 3529-3540 [PMID: 20653061]

18 **Chirdo FG**, Millington OR, Beacock-Sharp H, Mowat AM. Immunomodulatory dendritic cells in intestinal lamina propria. *Eur J Immunol* 2005; **35**: 1831-1840 [PMID: 16010704 DOI: 10.1002/eji.200425882]

19 **Mora JR**, Iwata M, Eksteen B, Song SY, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, Rajewsky K, Adams DH, von Andrian UH. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Science* 2006; **314**: 1157-1160 [PMID: 17110582 DOI: 10.1126/science.1132742]

20 **Kelsall BL**, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. *Immunol Rev* 2005; **206**: 132-148 [PMID: 16048546 DOI: 10.1111/j.0105-2896.2005.00292.x]

21 **Coombes JL**, Powrie F. Dendritic cells in intestinal immune regulation. *Nat Rev Immunol* 2008; **8**: 435-446 [PMID: 18500229 DOI: 10.1038/nri2335]

22 **Hart AL**, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. *Gastroenterology* 2005; **129**: 50-65 [PMID: 16012934]

23 **Long Y**, Wang W, Wang H, Hao L, Qian W, Hou X. Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome. *J Gastroenterol Hepatol* 2012; **27**: 935-944 [PMID: 22141367 DOI: 10.1111/j.1440-1746.2011.07046.x]

24 **Li M**, Zhang L, Lu B, Chen Z, Chu L, Meng L, Fan Y. Role of dendritic cell-mediated abnormal immune response in visceral hypersensitivity. *Int J Clin Exp Med* 2015; **8**: 13243-13250 [PMID: 26550249]

25 **Johansson C**, Kelsall BL. Phenotype and function of intestinal dendritic cells. *Semin Immunol* 2005; **17**: 284-294 [PMID: 15978836 DOI: 10.1016/j.smim.2005.05.010]

26 **Xue X**, Feng T, Yao S, Wolf KJ, Liu CG, Liu X, Elson CO, Cong Y. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. *J Immunol* 2011; **187**: 5879-5886 [PMID: 22068236 DOI: 10.4049/jimmunol.1100535]

27 **Han G**, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. *Front Immunol* 2013; **4**: 449 [PMID: 24339828 DOI: 10.3389/fimmu.2013.00449]

28 **Ocaña-Guzman R**, Torre-Bouscoulet L, Sada-Ovalle I. TIM-3 Regulates Distinct Functions in Macrophages. *Front Immunol* 2016; **7**: 229 [PMID: 27379093 DOI: 10.3389/fimmu.2016.00229]

29 **Sada-Ovalle I**, Chávez-Galán L, Torre-Bouscoulet L, Nava-Gamiño L, Barrera L, Jayaraman P, Torres-Rojas M, Salazar-Lezama MA, Behar SM. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. *J Immunol* 2012; **189**: 5896-5902 [PMID: 23180819 DOI: 10.4049/jimmunol.1200990]

30 **Jayaraman P**, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK, Behar SM. Tim3 binding to galectin-9 stimulates antimicrobial immunity. *J Exp Med* 2010; **207**: 2343-2354 [PMID: 20937702 DOI: 10.1084/jem.20100687]

31 **Dai SY**, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, Hata T, Nakamura T, Yamauchi A, Hirashima M. Galectin-9 induces maturation of human monocyte-derived dendritic cells. *J Immunol* 2005; **175**: 2974-2981 [PMID: 16116184]

32 **Zhang H**, Song Y, Yang H, Liu Z, Gao L, Liang X, Ma C. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. *Oncogene* 2018; **37**: 2456-2468 [PMID: 29449693 DOI: 10.1038/s41388-018-0140-4]

33 **Lawrance IC**, Wu F, Leite AZ, Willis J, West GA, Fiocchi C, Chakravarti S. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. *Gastroenterology* 2003; **125**: 1750-1761 [PMID: 14724828]

34 **La JH**, Kim TW, Sung TS, Kang JW, Kim HJ, Yang IS. Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. *World J Gastroenterol* 2003; **9**: 2791-2795 [PMID: 14669335]

35 **Al-Chaer ED**, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. *Gastroenterology* 2000; **119**: 1276-1285 [PMID: 11054385]

36 **Inaba K**, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1992; **176**: 1693-1702 [PMID: 1460426]

37 **Barbara G**, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? *Gut* 2002; **51 Suppl 1**: i41-i44 [PMID: 12077063]

38 **Raskov H**, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. *Gut Microbes* 2016; **7**: 365-383 [PMID: 27472486 DOI: 10.1080/19490976.2016.1218585]

39 **Ternovoĭ VA**, Shipitsyna VV, Iakovlev VM. [Changes in the content of various types of cholesterol and phospholipids in rat tissues during cold acclimation]. *Zh Evol Biokhim Fiziol* 1989; **25**: 15-19 [PMID: 2728689]

40 **Leonel AJ**, Alvarez-Leite JI. Butyrate: implications for intestinal function. *Curr Opin Clin Nutr Metab Care* 2012; **15**: 474-479 [PMID: 22797568 DOI: 10.1097/MCO.0b013e32835665fa]

41 **Ford AC**, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. *J Gastroenterol* 2011; **46**: 421-431 [PMID: 21331765 DOI: 10.1007/s00535-011-0379-9]

42 **Spiller RC**, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. *Gut* 2000; **47**: 804-811 [PMID: 11076879]

43 **Gwee KA**, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. *Gut* 2003; **52**: 523-526 [PMID: 12631663]

44 **Chadwick VS**, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. *Gastroenterology* 2002; **122**: 1778-1783 [PMID: 12055584]

45 **Wurbel MA**, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. *PLoS One* 2011; **6**: e16442 [PMID: 21283540 DOI: 10.1371/journal.pone.0016442]

46 **Drakes ML**, Blanchard TG, Czinn SJ. Colon lamina propria dendritic cells induce a proinflammatory cytokine response in lamina propria T cells in the SCID mouse model of colitis. *J Leukoc Biol* 2005; **78**: 1291-1300 [PMID: 16204624 DOI: 10.1189/jlb.0605342]

47 **Liebregts T**, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. *Gastroenterology* 2007; **132**: 913-920 [PMID: 17383420 DOI: 10.1053/j.gastro.2007.01.046]

48 **Maurya N**, Gujar R, Gupta M, Yadav V, Verma S, Sen P. Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src. *J Immunol* 2014; **193**: 3417-3425 [PMID: 25172495 DOI: 10.4049/jimmunol.1400395]

49 **Ndhlovu LC**, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. *Blood* 2012; **119**: 3734-3743 [PMID: 22383801 DOI: 10.1182/blood-2011-11-392951]

50 **Koh HS**, Chang CY, Jeon SB, Yoon HJ, Ahn YH, Kim HS, Kim IH, Jeon SH, Johnson RS, Park EJ. The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia. *Nat Commun* 2015; **6**: 6340 [PMID: 25790768 DOI: 10.1038/ncomms7340]

51 **Chen X**, Song CH, Liu ZQ, Feng BS, Zheng PY, Li P, In SH, Tang SG, Yang PC. Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine. *Allergy* 2011; **66**: 1038-1046 [PMID: 21426359 DOI: 10.1111/j.1398-9995.2011.02585.x]

52 **Jayaraman P**, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG, Behar SM. IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. *J Immunol* 2013; **190**: 4196-4204 [PMID: 23487424 DOI: 10.4049/jimmunol.1202688]

**P-Reviewer:** Maric I, Tanabe S **S-Editor:** Gong ZM

**L-Editor:** Wang TQ **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Photomicrographs of hematoxylin and eosin staining.** There was no difference with regard to morphology between control (A), IBS (B), IBS + *C. butyricum* (C), and IBS + NS (D) tissues in hematoxylin and eosin staining (original magnification, ×200) (*n* = 6 per group).



**Figure 2 Effects of *C. butyricum* on visceral hypersensitive in TNBS-induced irritable bowel syndrome mice.** The abdominal withdrawal reflex (AWR) scores at 0.25 ml (A), 0.35 ml (B), and 0.50 ml (C) distension volumes were measured on day 28. Data are expressed as the mean ± SEM (*n* = 6). a*P* < 0.05, b*P* < 0.05, c*P* < 0.05 *vs* control group, IBS + normal saline group, and IBS group, respectively. IBS: Irritable bowel syndrome.



**Figure 3 Effects of *C. butyricum* on the production of proinflammatory cytokines in irritable bowel syndrome mice.** Real-time PCR (A and B) and Western blot analysis(C-E) were used to measure the levels of proinflammatory cytokines IL-1β and IL-6. The results showed that IL-1β and IL-6 in the intestinal low-grade inflammatory state of IBS were significantly higher than those in the normal control group. The secretion of proinflammatory cytokines was significantly decreased after *C. butyricum* intervention. a*P* < 0.05, b*P* < 0.05, c*P* < 0.05 *vs* control group, IBS + normal saline group, and IBS group, respectively. IBS: Irritable bowel syndrome.



**Figure 4 Effects of *C. butyricum* on the quantity and functional status of the lamina propria dendritic cells.** A: Flow cytometry of CD11c+ LPDCs expression; B: Flow cytometry of CD11C+CD80+ LPDCs expression; C: Flow cytometry of CD11c+Tim3+ LPDCs expression; D: Flow scatter plot of all test indicators; E: Tim-3 mRNA levels measured by real-time PCR; F: Tim3 protein expression measured by Western blot analysis.The results showed that the expression of CD11c+, CD11C+CD80+, and CD11c+Tim3+ LPDCs in the intestinal inflammatory state of IBS was significantly higher than in that in the normal control group, and the costimulatory molecule CD80 representing DC in the activated mature state was also significantly increased (*P* < 0.01). However, the above indicators were significantly decreased after *C. butyricum* intervention. Our experimental results suggest that the LPDCs participate in and promote the intestinal inflammatory immune response of IBS and *C. butyricum* suppresses intestinal inflammation by reducing the number, function, and immunoregulatory molecule Tim3 of LPDCs in IBS mice. a*P* < 0.05, b*P* < 0.05, c*P* < 0.05 *vs* control group, IBS + normal saline group, and IBS group, respectively. IBS: Irritable bowel syndrome; LPDCs: lamina propria dendritic cells.

 **Figure 5 Effects of *C. butyricum* on the expression of Tim3 and inflammatory cytokines in bone marrow-derived dendritic cells.** LPS stimulated the proliferation and activation of bone marrow-derived dendritic cells (BMDCs). The expression of CD11c+CD80+ BMDCs and CD11c+Tim3+ BMDCs was significantly higher than that of the immature BMDCs group by flow cytometry (A-D). The inflammatory cytokines IL-1 and IL-6 detected by ELISA were also significantly elevated (E-F). Tim3 was highly expressed in mature activated BMDCs. Different forms of probiotics were co-cultured and stimulated with LPS. The expression of Tim3 was down-regulated with the decrease of inflammatory factors. It can be seen that Tim3 is the key point to regulate the activation of DCs. Clostridium butyricum can alter the activation status and function of DCs by regulating the expression of Tim3. a*P* < 0.05, b*P* < 0.05, c*P* < 0.05 *vs* ImBMDC group, BDMC group, and BDMC + LPS group, respectively. BMDCs:bone marrow-derived dendritic cells.